Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29186754 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL6190902 | 0.75 | CMA1 (0.75) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL6190639 | 0.75 | POLB (0.56) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL29895649 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL489133 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL1848968 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL7709830 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL435577 | 0.75 | PDE3B (0.59) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL118581 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL11538149 | 0.75 | CMA1 (0.41) | PDE3BPDE3APGRCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901153-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3288940-B9 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3288940-B1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3532477-B1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3532476-B1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-19 | — | — | EP | disclosed |
| EP-3288945-B1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-18 | — | — | EP | disclosed |
| US-20180251434-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2018-09-06 | — | — | US | disclosed |
| WO-2018080917-A1 | FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
| WO-2018080916-A1 | FUSED AZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251434-A1 | ANTIBACTERIAL HETEROCYCLIC DERIVATIVES | MRPL21, DCXR, Q6ZSR9 | PDE3B 1643/4885PDE3A 1843/4885PGR 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.